CompletedNot Applicable

Physical Activity Promoting Active Aging

China100 participantsStarted 2026-03-01

Plain-language summary

This project aims to explore the effects and underlying mechanisms of physical activity in promoting active aging among older adults. The researchers conducted two rounds of progressive randomized controlled intervention trials to verify the effects and mechanisms of a multimodal physical activity intervention on active aging from two dimensions: intervention structure and participation mode. In Study 1, with a 12-week intervention period, participants were randomly assigned to three groups: a Tai Chi exercise group, a multimodal exercise group, and a daily activity control group. By comparing between-group differences, the study evaluated the effects of different exercise modalities on physical function and subjective active aging. In Study 2, also with a 12-week intervention period, participants were randomly assigned to two multimodal exercise groups differing in participation mode: an in-person group-based format versus an online individual format. This study examined the moderating effects of different participation modes on both objective and subjective active aging outcomes, while keeping the multimodal physical activity intervention content identical.

Who can participate

Age range

60 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 60 years or above; Capable of engaging in regular physical activities and comprehending basic testing procedures and instructions. Exclusion Criteria: * Severe cardiac, pulmonary, or musculoskeletal disorders; History of neurological or psychiatric conditions that may impair cognitive function (e.g., stroke, Parkinson's disease, Alzheimer's disease, major depressive disorder, etc.); Missing three or more scheduled intervention sessions during the study period, or requesting discontinuation of participation.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Active aging

Timeframe: week0, week6, week12

General self-efficacy

Timeframe: week0, week6, week12

Cognitive function

Timeframe: week0, week6, week12

Cognitive function assessed by the Montreal Cognitive Assessment (MOCA)

Timeframe: week0, week6, week12

Trial details

NCT IDNCT07670208

SponsorYu Wang

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-20

View on ClinicalTrials.gov More Active Aging Individuals Aged 60 and Over trials

Plain-language summary

Who can participate

Age range

60 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.